| Effect of injectable and oral contraceptives on serum lipids. | |
| | |
MedLine Citation:
|
PMID: 19888036 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To estimate the effects of using depot medroxyprogesterone acetate (DMPA) or oral contraceptives (OCs) containing 20 micrograms ethinyl estradiol and 0.15 mg desogestrel on serum lipid levels. METHODS: Serum lipids were measured at baseline and every 6 months thereafter for 3 years in 703 white, African-American, and Hispanic women using DMPA, OC, or nonhormonal birth control. Those who discontinued DMPA were followed for up to 2 additional years. Participants completed questionnaires containing demographic and behavioral measures every 6 months and underwent 24-hour dietary recalls annually. Mixed-model regression analyses and general-estimating-equations procedures were used to estimate changes over time in lipids by method along with their predictors. RESULTS: Users of OCs experienced significantly greater increases in levels of triglycerides, total cholesterol, very-low-density lipoprotein (VLDL) cholesterol, and high-density lipoprotein (HDL) cholesterol than did nonhormonal-contraceptive users (P<.001). However, no difference was noted in the low-density lipoprotein (LDL) cholesterol:HDL ratio between OC users and nonhormonal-contraceptive users. Among DMPA users, HDL levels initially decreased for 6 months but then returned to baseline. The LDL:HDL ratio rose in the first 6 months of DMPA use but then dropped back to baseline over the next 24 months. After DMPA was discontinued, triglyceride, VLDL, and HDL levels were significantly higher in women who used OCs than in those who chose nonhormonal (P<.05) methods. CONCLUSION: Use of very-low-dose OCs containing desogestrel can elevate lipid levels. Users of DMPA were at increased risk of developing an abnormally low HDL level as well as an abnormally high LDL level and an increase in the LDL:HDL cholesterol ratio, although these effects appeared to be temporary. LEVEL OF EVIDENCE: II. |
| | |
Authors:
|
Abbey B Berenson; Mahbubur Rahman; Gregg Wilkinson |
Related Documents
:
|
231466 - Cutaneous cholesterol and plasma lipoproteins in young subjects. 6712536 - Plasma triglyceride determines structure-composition in low and high density lipoproteins. 4036756 - Ascorbic acid effect on some lipid fractions in human beings. 16401396 - Phytopreventative anti-hyperlipidemic effects of gynostemma pentaphyllum in rats. 16133196 - Higher pollinator effectiveness by specialist than generalist flower-visitors of unspec... 3620336 - The influence of diet and dimethylhydrazine on the large intestine of vervet monkeys: s... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Obstetrics and gynecology Volume: 114 ISSN: 0029-7844 ISO Abbreviation: Obstet Gynecol Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-11-05 Completed Date: 2009-12-02 Revised Date: 2010-12-03 |
Medline Journal Info:
|
Nlm Unique ID: 0401101 Medline TA: Obstet Gynecol Country: United States |
Other Details:
|
Languages: eng Pagination: 786-94 Citation Subset: AIM; IM |
Affiliation:
|
Department of Obstetrics and Gynecology, the Center for Interdisciplinary Research in Women's Health, the University of Texas Medical Branch, Galveston, Texas 77555-0587, USA. abberens@utmb.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult African Americans Cholesterol / blood Contraceptives, Oral / pharmacology* Desogestrel / pharmacology* Ethinyl Estradiol / pharmacology* European Continental Ancestry Group Female Hispanic Americans Humans Hypercholesterolemia / chemically induced* Hypertriglyceridemia / chemically induced* Longitudinal Studies Medroxyprogesterone Acetate / pharmacology* Triglycerides / blood Young Adult |
| Grant Support | |
ID/Acronym/Agency:
|
K24 HD043659-01/HD/NICHD NIH HHS; K24 HD043659-02/HD/NICHD NIH HHS; K24 HD043659-03/HD/NICHD NIH HHS; K24 HD043659-04/HD/NICHD NIH HHS; K24 HD043659-05/HD/NICHD NIH HHS; K24 HD043659-06/HD/NICHD NIH HHS; K24 HD043659-07/HD/NICHD NIH HHS; K24 HD043659-09/HD/NICHD NIH HHS; K24HD043659/HD/NICHD NIH HHS; M01 RR000073-41S10528/RR/NCRR NIH HHS; M01 RR000073-42A10528/RR/NCRR NIH HHS; M01 RR000073-438696/RR/NCRR NIH HHS; M01 RR000073-447287/RR/NCRR NIH HHS; M01 RR000073-455386/RR/NCRR NIH HHS; M01RR00073/RR/NCRR NIH HHS; R01 HD039883-01A1/HD/NICHD NIH HHS; R01 HD039883-02/HD/NICHD NIH HHS; R01 HD039883-02S1/HD/NICHD NIH HHS; R01 HD039883-03/HD/NICHD NIH HHS; R01 HD039883-03S3/HD/NICHD NIH HHS; R01 HD039883-04/HD/NICHD NIH HHS; R01 HD039883-05/HD/NICHD NIH HHS; R01HD039883/HD/NICHD NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Contraceptives, Oral; 0/Triglycerides; 54024-22-5/Desogestrel; 57-63-6/Ethinyl Estradiol; 57-88-5/Cholesterol; 71-58-9/Medroxyprogesterone Acetate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of hot flushes on vascular function: a randomized controlled trial.
Next Document: Immediate complications after medical compared with surgical termination of pregnancy.